Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case‐series analysis from the Italian Rare Cancers Network

医学 四分位间距 伊马替尼 内科学 无进展生存期 回顾性队列研究 脊索瘤 外科 肿瘤科 胃肠病学
作者
Giacomo Giulio Baldi,Salvatore Lo Vullo,Giovanni Grignani,Bruno Vincenzi,Giuseppe Badalamenti,Marinella Mastore,Ciriaco Buonomenna,Carlo Morosi,Marta Barisella,Anna Maria Frezza,Salvatore Provenzano,Noemi Simeone,Fernanda Picozzi,Luigi Mariani,Paolo Giovanni Casali,Silvia Stacchiotti
出处
期刊:Cancer [Wiley]
卷期号:128 (7): 1439-1448 被引量:11
标识
DOI:10.1002/cncr.34083
摘要

BACKGROUND: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. METHODS: Adult patients with a diagnosis of advanced, brachyury-positive chordoma, treated from April 2007 to October 2020 with wCDDP or wCDDP/I were retrospectively identified. Imatinib was withheld at the same time as wCDDP. Response according to Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS) were analyzed. RESULTS: Thirty-three consecutive patients were identified (wCDDP as front-line n = 8 [24.2%]; wCDDP as a further line n = 25 [75.8%]; prior imatinib n = 25 [75.8%]; evidence of progression before starting wCDDP n = 33). Of 32 patients evaluable for response (wCDDP, n = 22 [68.8%]; wCDDP/I, n = 10 [31.3%]), best response was stable disease (SD) in 27 patients (84.3%) and progression in 5 patients (15.6%). At a median follow-up of 54 months, the median OS (m-OS) was 30.3 months (interquartile range [IQR], 18.1-56.6), the m-PFS was 8.0 months (IQR, 5.1-17.0), the 6-month PFS rate was 65.2%, and the 12-month PFS rate was 30.3%. Of 22 patients who received wCDDP, the best response was SD in 18 patients (81.8%) and progression in 4 patients (18.2%), and the m-PFS was 8.0 months (IQR, 5.1-17.0 months). Of 10 patients who received treatment with wCDDP/I, the best response was SD in 9 patients (90%) and progression in 1 patient (10%), and the m-PFS was 9.3 months (IQR, 4.9-26.5 months). CONCLUSIONS: This series suggests that wCDDP, both as a single agent and combined with imatinib, has antitumor activity in chordoma. Although no dimensional responses were observed, 65% and 30% of previously progressive patients were progression-free at 6 and 12 months, respectively. A prospective study is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研雾完成签到,获得积分10
刚刚
maoqiuzhao发布了新的文献求助10
1秒前
molihuakai的应助被文献互助1采纳,获得10
1秒前
bkagyin的应助被rose采纳,获得10
1秒前
maoamo2024发布了新的文献求助10
2秒前
yu完成签到,获得积分10
2秒前
田様的应助被路小雨采纳,获得10
2秒前
2秒前
2秒前
久睡成瘾完成签到,获得积分10
3秒前
清辉影的应助被yuxing采纳,获得10
3秒前
Jan完成签到,获得积分0
3秒前
Tuniverse_发布了新的文献求助10
4秒前
温柔的百川完成签到,获得积分10
4秒前
喂喂喂发布了新的文献求助10
5秒前
Yaoz完成签到,获得积分10
5秒前
许元冬完成签到,获得积分10
5秒前
zft完成签到,获得积分10
5秒前
KBRS完成签到,获得积分10
6秒前
MM完成签到,获得积分10
7秒前
雪雪完成签到,获得积分10
8秒前
Yaoz发布了新的文献求助30
9秒前
明亮绮菱发布了新的文献求助10
9秒前
xiang完成签到,获得积分10
11秒前
11秒前
缥缈幻悲完成签到,获得积分10
11秒前
王明月完成签到,获得积分10
12秒前
彭映梦完成签到 ,获得积分10
13秒前
小小酥被卷了完成签到,获得积分10
14秒前
科研通AI6.4的应助被obito采纳,获得10
16秒前
天真酸奶的应助被obito采纳,获得10
16秒前
CipherSage的应助被明亮绮菱采纳,获得10
16秒前
王明月发布了新的文献求助10
16秒前
Gyqqqq完成签到,获得积分10
17秒前
Owen的应助被feisun采纳,获得10
18秒前
18秒前
难过含烟完成签到 ,获得积分10
19秒前
likun完成签到,获得积分10
19秒前
20秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621